This study recruited a total of 186 patients with HGG who were treated with temozolomide plus radiotherapy adjuvant regimen...the relevance of 313A>G polymorphism to PFS of the 186 patients with HGG suggested that the median PFS of patients with AA and AG/GG genotype was 11.2 months (95% CI: 8.69–13.71) and 5.0 months (95% CI: 3.99–6.01), respectively. And the difference was statistically significant (χ2=11.17, P=0.001)....The OS survival curve according to 313A>G genotype status was exhibited in Figure 3. Accordingly, the median OS of patients with AA genotype and AG/GG genotype was 18.9 months (95% CI: 14.82–22.98) and 10.5 months (95% CI: 7.34–13.66), respectively. And the difference was statistically significant (χ2=12.684, P<0.001).